Dovitinib is primarily used in the treatment of various cancers due to its ability to inhibit multiple tyrosine kinases, which play a critical role in cancer cell growth and survival. It is particularly studied in renal cell carcinoma (RCC), where it targets pathways like VEGF and FGF, which are often dysregulated in this type of cancer. Additionally, it has shown potential in treating gastrointestinal stromal tumors (GIST) and certain types of breast cancer by blocking signaling pathways that promote tumor progression. Dovitinib is also being explored in combination therapies to enhance its efficacy and overcome resistance to other cancer treatments. Its broad-spectrum kinase inhibition makes it a versatile candidate for targeting multiple oncogenic pathways simultaneously.